Diclofenac vs Aceclofenac - A Detailed Comparison

1. Chemical Classification

2. Mechanism of Action (COX Selectivity)

• Relatively nonselective COX inhibitor (inhibits both COX-1 and COX-2)
• In short-term in vitro tests: COX-1 IC50 = 0.43 µmol/L, COX-2 IC50 = 0.0054 µmol/L
• In long-term tests: COX-1 IC50 = 0.16, COX-2 IC50 = 0.024 µmol/L
• Direct, immediate inhibitor

• Preferential COX-2 inhibitor (IC50 COX-2/COX-1 ratio ~0.26)
• In short-term tests: NO direct inhibition of either COX isoform
• In long-term tests: COX-1 IC50 = 3.59, COX-2 IC50 = 1.65 µmol/L
• Inhibits COX only AFTER biotransformation to diclofenac and 4'-hydroxydiclofenac
• This "limited but sustained" conversion to diclofenac explains its preferential COX-2 effect

• Inhibits pro-inflammatory cytokines IL-1β and TNF-α
• Inhibits prostaglandin E2 (PGE2) production in synovial fluid
• Inhibits reactive oxygen species
• Suppresses expression of cell adhesion molecules in neutrophils
• Inhibits COX-2 synthesis in synovial membrane (demonstrated in OA patients)

3. Pharmacokinetics

4. Clinical Efficacy

• Osteoarthritis (OA)
• Rheumatoid arthritis (RA)
• Ankylosing spondylitis (AS)
• Acute pain (dental, post-operative, dysmenorrhea)
• Low back pain (LBP)

• In a 12-week multicenter RCT in knee OA, both drugs showed significant improvement in pain intensity (p=0.0001); 71% of aceclofenac patients reported pain improvement vs 59% in the diclofenac group (p=0.005)
• In patients with initial flexion deformity of the knee, aceclofenac was significantly more effective than diclofenac in improving knee flexion at 2-4 weeks
• In OA (WOMAC scoring), aceclofenac showed superior scores vs diclofenac over 8 weeks
• In acute dental pain, aceclofenac 100 mg once daily showed equal efficacy to diclofenac sodium 50 mg twice daily
• In axial spondyloarthritis studies (from the Rheumatology textbook), both drugs are listed as equally effective compared to indomethacin at standard doses
• Multiple RCTs summarized in systematic reviews confirm aceclofenac is "at least as effective as diclofenac, naproxen, piroxicam, indomethacin" in OA/RA/AS

5. Adverse Effects

6. Drug Interactions

7. Available Formulations

• Oral: sodium salt 25 mg, 50 mg; potassium salt 50 mg; SR 75 mg, 100 mg
• Topical: 1% gel (OTC for OA, muscular pain), 3% gel
• Ophthalmic: 0.1% solution
• Rectal suppository
• IM injection (Europe)
• Combination: diclofenac + misoprostol (Arthrotec), diclofenac + omeprazole

• Oral: 100 mg tablets (most common)
• Topical: gels (available in some markets)
• Combination with paracetamol, serratiopeptidase, thiocolchicoside widely available in India/Asia

8. Practical Prescribing Summary

Bottom Line

1. Preferential COX-2 selectivity (via controlled conversion to diclofenac) - reducing GI adverse effects
2. Longer half-life - allowing BD vs TID dosing
3. Additional cytokine-inhibiting mechanisms - potentially broader anti-inflammatory coverage
4. Comparable or marginally superior efficacy in OA/RA/LBP

Sources: Katzung's Basic and Clinical Pharmacology 16th ed.; Rheumatology 2-Volume Set (Elsevier, 2022); PMC6052370 (Diclofenac in rheumatic diseases review); comparative RCTs from Springer Clinical Rheumatology and Indian experience studies.

Aceclofenac as a Derivative of Diclofenac

Structural Relationship

Diclofenac:    Ar-NH-Ph-CH₂-COOH
Aceclofenac:   Ar-NH-Ph-CH₂-COO-CH₂-COOH
                              ↑
                    glycolic ester linkage added here

Is it a Prodrug?

• Technically: Aceclofenac is more accurately called an analog rather than a classic prodrug
• A true prodrug is pharmacologically inert and only works after conversion to the active drug
• Aceclofenac has its own intrinsic pharmacological activity - it inhibits COX (in long-term tests), inhibits IL-1β, TNF-α, and PGE2 independently
• However, part of its activity does come from metabolic conversion to diclofenac (~20-30% undergoes hydrolysis to diclofenac in vivo)
• So it behaves as a partial prodrug / active metabolite drug

What Happens In Vivo

Aceclofenac
     │
     ├──→ 4'-hydroxyaceclofenac  (own anti-inflammatory activity)
     │
     ├──→ Diclofenac  (~20-30% conversion)
     │         │
     │         └──→ 4'-hydroxydiclofenac  (active)
     │
     └──→ Direct COX-2 inhibition (own effect)

Why the Ester Modification Was Made

One-Line Answer

Why the Glycolic Ester Gives Aceclofenac Better GI Safety

Step 1 - First Understand Why NSAIDs Damage the GI Tract At All

• Stimulate mucus and bicarbonate secretion (physical barrier against acid)
• Maintain gastroduodenal blood flow
• Promote mucosal cell renewal and repair
• Suppress parietal cell acid secretion

"COX-1 generates prostanoids for 'housekeeping' functions, such as gastric epithelial cytoprotection, whereas COX-2 is the major source of prostanoids in inflammation."

Step 2 - How Diclofenac Damages the GI Tract

Hit 1 - Direct Topical Injury (local/chemical)

• The free -COOH group of diclofenac is ionizable and lipophilic at gastric pH
• At low gastric pH, diclofenac becomes uncharged (non-ionized) and fat-soluble
• It diffuses directly into gastric epithelial cells, bypassing the mucus layer
• Once inside the cell (higher pH), it becomes re-ionized and trapped - this is called ion trapping
• Trapped acid accumulates intracellularly, disrupting mitochondria, uncoupling oxidative phosphorylation, and causing direct cell death
• This is a COX-independent mechanism - it would damage the mucosa even without any COX inhibition

Hit 2 - Systemic COX-1 Inhibition

• After absorption, diclofenac circulates and inhibits COX-1 in the gastric mucosa via the bloodstream
• This reduces prostaglandin synthesis, stripping away the cytoprotective layer
• Mucus production falls, blood flow decreases, and the mucosa becomes vulnerable

Step 3 - How the Glycolic Ester Modification Blocks Both Hits

Diclofenac:     -CH₂-COOH        ← free acid, ionizable, locally toxic
Aceclofenac:    -CH₂-COO-CH₂-COOH  ← ester bond masks the acetic acid group

Blocking Hit 1 - No Direct Topical Injury

• The ester bond prevents the direct penetration mechanism
• Aceclofenac cannot ion-trap inside gastric mucosal cells because the acid group responsible for it is blocked
• An endoscopic study (Yanagawa et al., 1998) showed that:
  • Diclofenac significantly reduced gastric mucosal hexosamine content and gastroduodenal blood flow
  • Aceclofenac increased gastric mucosal hexosamine (a marker of mucus integrity) and left blood flow unchanged
  • Direct endoscopic comparison confirmed far less mucosal damage with aceclofenac

Blocking Hit 2 - Less Systemic COX-1 Inhibition

• Aceclofenac is absorbed intact (the ester is stable in the GI lumen)
• It is only hydrolyzed to diclofenac after absorption, primarily in the liver and systemic circulation
• The amount of diclofenac generated is limited and controlled (~20-30% conversion)
• The resulting plasma diclofenac concentration (0.39 µmol/L) is about 3x lower than after an equivalent oral diclofenac dose (1.28 µmol/L)
• Lower systemic diclofenac = less COX-1 inhibition in the gut mucosa
• Importantly, this lower concentration is still sufficient to achieve >97% COX-2 inhibition (COX-2 IC50 = 0.024 µmol/L), so anti-inflammatory efficacy is preserved

Step 4 - The COX-2 Selectivity Contribution

• At inflammatory sites (joints, tissues): COX-2 is inhibited - anti-inflammatory effect achieved
• In the stomach (COX-1 dominant): much less inhibition - gastroprotective prostaglandins preserved

Summary Diagram

                    GASTRIC MUCOSA
                          │
                    COX-1 activity
                          │
               Protective PGs (PGE2, PGI2)
                    /           \
               Mucus/HCO₃⁻    Mucosal blood flow
                    \           /
                  Mucosal integrity

DICLOFENAC:
  Free -COOH → ion trapping → direct cell death        [Hit 1]
  High COX-1 inhibition → PG loss → barrier fails      [Hit 2]
  ↓↓↓ mucosal hexosamine, ↓↓↓ blood flow

ACECLOFENAC:
  Ester blocks -COOH → NO ion trapping                 [Hit 1 blocked]
  Low COX-1 inhibition → PGs largely preserved         [Hit 2 reduced]
  ↑ mucosal hexosamine, blood flow unchanged

Clinical Numbers (Large SAMM Study, n=10,142)

One-Sentence Mechanistic Summary

Sources: Katzung's Basic and Clinical Pharmacology 16th ed.; PMC8643213 (Aceclofenac Review, Dove Medical Press); Yanagawa et al. 1998 endoscopic study; SAMM pharmacovigilance study (n=10,142).